Comparative Pharmacology
Head-to-head clinical analysis: CEPHALOTHIN SODIUM W DEXTROSE IN PLASTIC CONTAINER versus OMNICEF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEPHALOTHIN SODIUM W DEXTROSE IN PLASTIC CONTAINER versus OMNICEF.
CEPHALOTHIN SODIUM W/ DEXTROSE IN PLASTIC CONTAINER vs OMNICEF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cephalothin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It has bactericidal activity against susceptible gram-positive and some gram-negative bacteria.
Cephalosporin antibiotic; inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
1-2 g IV every 4-6 hours; maximum 12 g/day.
300 mg orally twice daily for 10 days; or 600 mg orally once daily for 10 days (for community-acquired pneumonia, acute exacerbations of chronic bronchitis, sinusitis, pharyngitis/tonsillitis, uncomplicated skin infections).
None Documented
None Documented
30-60 minutes in normal renal function; prolonged to 2-8 hours in severe renal impairment (CrCl <10 mL/min).
1.7 hours (range 1.2–2.3 h) in healthy adults; prolonged to 3.2–6.6 h in renal impairment (CrCl <30 mL/min); no significant change in hepatic impairment.
Primarily renal (60-70% unchanged) via glomerular filtration and tubular secretion; minor biliary (5-10%) and fecal (<1%) elimination.
Renal excretion as unchanged drug: 80-90% (primarily via glomerular filtration and tubular secretion); biliary/fecal: 10-20% (minor).
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic